ICOTYDE (icotrokinra)
Moderate-to-Severe Plaque Psoriasis
ApprovedApproved (FDA Mar 2026)
Key Facts
Indication
Moderate-to-Severe Plaque Psoriasis
Phase
Approved
Status
Approved (FDA Mar 2026)
About johnson-and-johnson-innovative-medicine
Johnson & Johnson Innovative Medicine, established as a clarified entity in 2023 following the Kenvue spin-off, is a global pharmaceutical leader with a mission to transform healthcare through high-impact science. Its strategy integrates deep internal R&D with strategic business development to build a leading pipeline across oncology, immunology, neuroscience, and cardiopulmonary diseases. Recent achievements include the FDA approval of the first-in-class oral peptide ICOTYDE™ for psoriasis and the expansion of its multiple myeloma regimen, demonstrating its capacity for innovation and commercial execution within the J&J conglomerate.
View full company profileTherapeutic Areas
Other Moderate-to-Severe Plaque Psoriasis Drugs
| Drug | Company | Phase |
|---|---|---|
| AC-201 | Accro Bioscience | Phase 2 |
| TAK-279 (NDI-034858) | Takeda | Phase 3 |
| ILUMYA® (tildrakizumab-asmn) | Sun Pharmaceutical | Commercial |
| Iruxolimab (AK101) | Akeso | Approved |
| Icotrokinra (JNJ-2113) | Protagonist Therapeutics | Approved |
| Envudeucitinib (ESK-001) | Alumis | Phase 3 |
| ORKA-001 | Oruka Therapeutics | Phase 1/2 |